+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Renal Failure Treatment Market Size, Share and Trends Analysis Report by Treatment (Dialysis, Kidney Transplantation, Drug Therapy), End-use (Hospitals, Specialty Clinics), and Region 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • September 2024
  • Region: Global
  • Grand View Research
  • ID: 6009721
The global renal failure treatment market size is anticipated to reach USD 197.1 billion by 2030 and is anticipated to grow at a CAGR of 8.3% from 2024 to 2030. The market encompasses a range of products and services designed to manage and treat chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The increasing prevalence of chronic kidney disease is a significant market driver. The growing incidence is largely attributed to the rising rates of diabetes and hypertension, which are known risk factors for kidney disease. As the population ages and these chronic conditions become more prevalent, the need for renal failure treatment continues to grow, placing additional pressure on healthcare systems to provide adequate care.

Rising awareness and education about kidney health are crucial market drivers. Public health campaigns and initiatives aimed at educating individuals about the risks and symptoms of kidney disease have contributed to earlier diagnosis and treatment. The heightened awareness encourages patients to seek medical advice sooner, ultimately leading to timely interventions and improved management of kidney conditions.

In October 2023, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) entered a licensing agreement to co-commercialize Desidustat, the first oral drug in India to treat anemia caused by chronic kidney disease (CKD). The licensing agreement for Desidustat represents a significant development in the market by providing a novel oral treatment option for anemia associated with CKD, enhancing patient care, and expanding market access in India.

Renal Failure Treatment Market Report Highlights

  • Based on treatment, dialysis dominated the market with the largest revenue share of 72.34% in 2023. The rising prevalence of CKD and ESRD is driving the demand for renal replacement therapies. Major factors contributing to this trend include an aging population, technological advancements in dialysis, and increased kidney health awareness
  • Based on end-use, hospitals dominated the market with the largest revenue share of 57.64% in 2023. Factors driving this growth include a rise in patient admissions for dialysis and transplant procedures, technological advancements in renal care equipment, and comprehensive healthcare services provided by hospitals that cater to complex cases

The leading players in the Renal Failure Treatment market include:

  • NIPRO
  • Fresenius Medical Care AG,
  • Baxter
  • Medtronic
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • Nikkiso Co., Ltd.
  • JMS Co., Ltd.
  • AstraZeneca

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Renal Failure Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increased prevalence of CKD
3.2.1.2. Advancements in treatment technologies
3.2.1.3. Rising awareness and education about kidney health
3.2.1.4. Aging population
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Limited Healthcare Resources and Access
3.3. Renal Failure Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Renal Failure Treatment Market: Treatment Estimates & Trend Analysis
4.1. Global Renal Failure Treatment Market: Treatment Dashboard
4.2. Global Renal Failure Treatment Market: Treatment Movement Analysis
4.3. Global Renal Failure Treatment Market by Treatments, Revenue
4.4. Dialysis
4.4.1. Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. Hemodialysis
4.4.2.1. Hemodialysis market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. Peritoneal Dialysis
4.4.3.1. Peritoneal Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Kidney Transplantation
4.5.1. Kidney transplantation market estimates and forecasts 2018 - 2030 (USD Million)
4.6. Drug Therapy
4.6.1. Drug therapy market estimates and forecasts 2018 - 2030 (USD Million)
4.6.2. Antihypertensive Drugs
4.6.2.1. Antihypertensive Drugs market estimates and forecasts 2018 - 2030 (USD Million)
4.6.3. Antianemia Therapeutics (Erythropoiesis-Stimulating Agents)
4.6.3.1. Antianemia therapeutics (Erythropoiesis-Stimulating Agents) market estimates and forecasts 2018 - 2030 (USD Million)
4.6.4. Potassium Binders
4.6.4.1. Potassium Binders market estimates and forecasts 2018 - 2030 (USD Million)
4.6.5. Phosphate Binders
4.6.5.1. Phosphate Binders market estimates and forecasts 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Renal Failure Treatment Market: End Use Estimates & Trend Analysis
5.1. Global Renal Failure Treatment Market: End Use Dashboard
5.2. Global Renal Failure Treatment Market: End Use Movement Analysis
5.3. Global Renal Failure Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Million)
5.5. Specialty Clinics
5.5.1. Specialty clinics market estimates and forecasts 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Renal Failure Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use
6.1. Regional Dashboard
6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. NIPRO
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Fresenius Medical Care AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Baxter
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Medtronic
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. B. Braun SE
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Asahi Kasei Medical Co., Ltd.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. AbbVie Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Nikkiso Co., Ltd.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. JMS Co., Ltd.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. AstraZeneca
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America renal failure treatment market, by region, 2018 - 2030 (USD Million)
Table 3 North America renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 4 North America renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 5 U.S. renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 6 U.S. renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 7 Canada renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 8 Canada renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 9 Mexico renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 10 Mexico renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 11 Europe renal failure treatment market, by region, 2018 - 2030 (USD Million)
Table 12 Europe renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 13 Europe renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 14 Germany renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 15 Germany renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 16 UK renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 17 UK renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 18 France renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 19 France renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 20 Italy renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 21 Italy renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 22 Spain renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 23 Spain renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 24 Denmark renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 25 Denmark renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 26 Sweden renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 27 Sweden renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 28 Norway renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 29 Norway renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 30 Asia Pacific renal failure treatment market, by region, 2018 - 2030 (USD Million)
Table 31 Asia Pacific renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 32 Asia Pacific renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 33 China renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 34 China renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 35 Japan renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 36 Japan renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 37 India renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 38 India renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 39 South Korea renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 40 South Korea renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 41 Australia renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 42 Australia renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 43 Thailand renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 44 Thailand renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 45 Latin America renal failure treatment market, by region, 2018 - 2030 (USD Million)
Table 46 Latin America renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 47 Latin America renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 48 Brazil renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 49 Brazil renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 50 Argentina renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 51 Argentina renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 52 MEA renal failure treatment market, by region, 2018 - 2030 (USD Million)
Table 53 MEA renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 54 MEA renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 55 South Africa renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 56 South Africa renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 59 UAE renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 60 UAE renal failure treatment market, by end use, 2018 - 2030 (USD Million)
Table 61 Kuwait renal failure treatment market, by treatment, 2018 - 2030 (USD Million)
Table 62 Kuwait renal failure treatment market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Market research approaches
Fig. 4 QFD modeling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Renal failure treatment market: market outlook
Fig. 7 Renal failure treatment competitive insights
Fig. 8 Parent market outlook
Fig. 9 Related/ancillary market outlook
Fig. 10 Renal failure treatment market driver impact
Fig. 11 Renal failure treatment market restraint impact
Fig. 12 Renal failure treatment market: Treatment movement analysis
Fig. 13 Renal failure treatment market: Treatment outlook and key takeaways
Fig. 14 Dialysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 15 Hemodialysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Peritoneal dialysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Kidney transplantation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Drug therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Antihypertensive drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Antianemia therapeutics (erythropoiesis-stimulating agents) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Potassium binders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phosphate binders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Renal failure treatment market: End use movement analysis
Fig. 25 Renal failure treatment market: End use outlook and key takeaways
Fig. 26 Hospital market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Global renal failure treatment market: Regional movement analysis
Fig. 30 Global renal failure treatment market: Regional outlook and key takeaways
Fig. 31 Global renal failure treatment market share and leading players
Fig. 32 North America, by country
Fig. 33 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 U.S. key country dynamics
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Canada key country dynamics
Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Mexico key country dynamics
Fig. 39 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 UK key country dynamics
Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Germany key country dynamics
Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 France key country dynamics
Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Italy key country dynamics
Fig. 48 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Spain key country dynamics
Fig. 50 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Denmark key country dynamics
Fig. 52 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Sweden key country dynamics
Fig. 54 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Norway key country dynamics
Fig. 56 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 China key country dynamics
Fig. 59 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Japan key country dynamics
Fig. 61 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 India key country dynamics
Fig. 63 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Thailand key country dynamics
Fig. 65 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 South Korea key country dynamics
Fig. 67 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Australia key country dynamics
Fig. 69 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Brazil key country dynamics
Fig. 72 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Argentina key country dynamics
Fig. 74 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 South Africa key country dynamics
Fig. 77 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Saudi Arabia key country dynamics
Fig. 79 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 UAE key country dynamics
Fig. 81 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Kuwait key country dynamics
Fig. 83 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Market share of key market players- renal failure treatment market

Companies Mentioned

The leading players in the Renal Failure Treatment market include:
  • NIPRO
  • Fresenius Medical Care AG,
  • Baxter
  • Medtronic
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • Nikkiso Co., Ltd.
  • JMS Co., Ltd.
  • AstraZeneca

Methodology

Loading
LOADING...

Table Information